•
Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status of two levornidazole specifications manufactured by Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), citing the need for intellectual property (IP) protection. Additionally, Anhui province has also paused the procurement of two levornidazole specifications made by…
•
China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou Smart Nuclide Pharmaceutical Technology Company, a move focused on the development of radioactive drugs based on conjugate technology. Complementary Expertise in RadiopharmaceuticalsUnder the terms of the partnership, Tot Bio will offer a comprehensive antibody conjugate…
•
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of a two-dose schedule for its bivalent recombinant human papillomavirus (HPV) vaccine, Cervarix (types 16 and 18), targeting girls aged 9 to 14 in China. Cervarix’s Approval History and Expansion in ChinaCervarix was first approved in…
•
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN), has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary. This marks the beginning of a new treatment era for IgA nephropathy…
•
Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire an 87.5% stake in US-based liquid embolic agent specialist BlackSwan Vascular Inc., for USD 37.5 million. This strategic move signifies Grand Pharma’s commitment to expanding its global presence in the medical device industry. BlackSwan Vascular…
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 product candidate, ZG2001. ZG2001 is an in-house discovered oral pan-KRAS mutation inhibitor under development for the treatment of KRAS mutant tumors. Prevalence…
•
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval from the National Medical Products Administration (NMPA) to conduct two clinical studies. One study will investigate the combination of its drug candidate BL-B01D1 with osimertinib (Tagrisso) for the treatment of locally advanced or metastatic non-small…
•
YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its financial report for 2022, recording revenues of RMB 3.745 billion (USD 582.8 million), marking a substantial increase of 309.83% year-on-year (YOY). The company transitioned from a previous year loss to achieve net profits of RMB…
•
China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General Manager (GM), Pascal Qian, to the position of Chief Commercial Officer (COO). This strategic move comes as LianBio prepares for the potential market launch of mavacamten, a first-in-class molecule for the treatment of obstructive hypertrophic…
•
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has announced a strategic partnership with Qitan Tech, a Chengdu-based nanopore gene sequencer manufacturer. The collaboration aims to drive technology development, regulatory filings, localization, and industrialization of nanopore gene sequencers in the preimplantation genetic testing (PGT)…
•
Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its small-molecule HER2 inhibitor, pyrotinib. The drug is now approved for use in combination with Herceptin (trastuzumab) plus chemotherapy to treat recurrent or metastatic breast cancer…
•
Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a Phase I/II clinical study for its antibody-drug conjugate (ADC), XNW27011. The study will focus on locally advanced unresectable or metastatic malignant solid tumors expressing Claudin 18.2 (CLDN18.2).…
•
The National Health Commission (NHC) has released a notification with the goal of promoting enhanced recovery after surgery (ERAS) services across China. ERAS, as defined by the American Association of Nurse Anesthesiology, is a patient-centered, evidence-based approach developed by multidisciplinary teams for a surgical specialty and facility. The focus is…
•
ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its generic version of Shire’s Firazyr (icatibant). This marks a significant milestone as the company becomes the first manufacturer to file for Drug…
•
China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140 million (USD 20.3 million) in the establishment of a private equity fund with a total value of RMB 500 million (USD 72.5 million). The fund will focus on investments in vaccine companies, highlighting CanSino’s commitment…
•
Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of Global Depositary Receipt (GDR) shares. A total of 34 million shares of common stock were offered at a price of USD 13.61 per share, resulting in a capital raise of USD 462.7 million. The shares…
•
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD 1.233 billion (USD 157 million) in revenues, marking a 2.6% year-on-year (YOY) decrease. In-licensed products contributed HKD 733 million (USD 93.73 million), accounting for 59.5% of total revenues, while patented drugs and generics made up…
•
Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment of USD 100 million in 2018, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, RSS0343, intended to treat non-cystic fibrosis bronchiectasis (NCFB). Understanding Non-Cystic Fibrosis Bronchiectasis…
•
German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center to launch the “Rising Star smart chest pain center standardized construction training program.” This initiative is designed to enhance the standardized construction of chest pain treatment processes and improve clinical intervention diagnosis and treatment capabilities.…
•
Nanjing-based Neurodawn Pharmaceutical Co., Ltd has announced that its Category 1 drug, injectable Y-1, has obtained clinical trial approval from the National Medical Products Administration (NMPA) for the treatment of primary intracranial malignant tumors. TRPML1 Inhibitor’s Non-Clinical Study ResultsNon-clinical studies have demonstrated that the TRPML1 inhibitor, Y-1, can effectively inhibit…